| Jennifer Ruth Wood, | |
|
87 N 200 E Ste 302, St George, UT 84770-5019 | |
| (435) 922-2750 | |
| (435) 922-2759 |
| Full Name | Jennifer Ruth Wood |
|---|---|
| Gender | Female |
| Speciality | Case Manager/care Coordinator |
| Location | 87 N 200 E Ste 302, St George, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144975053 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Ruth Wood, 1624 Redstone Way, St George, UT 84790-8590 Ph: (435) 633-5368 | Jennifer Ruth Wood, 87 N 200 E Ste 302, St George, UT 84770-5019 Ph: (435) 922-2750 |
News Archive
In a review published in the April issue of Immunity, Kevin J. Tracey, MD, president of The Feinstein Institute for Medical Research, says it's time to take a fresh look at the medical community's approach to treating sepsis, which kills millions worldwide every year, including more than 200,000 Americans.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
Cardiac imaging researchers at Cedars-Sinai Heart Institute are recommending that physicians not overlook fatty deposits around the heart when evaluating patients for risk of major heart problems.
Mount Sinai researchers have pinpointed a single gene biomarker, nitride oxide synthase 2 (NOS2) that can distinguish atopic dermatitis (AD) and psoriasis with 100 percent accuracy using adhesive tape strips, a non-invasive alternative to skin biopsy. The research will be published online today in the Journal of Allergy and Clinical Immunology.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic.
› Verified 7 days ago